The global cellular starting materials market size is anticipated to reach USD 4.84 billion by 2030, growingand is anticipated to expand at a CAGR of 22.74% from 2024 to 2030, according to a new report. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, rising investments, growing demand for cell and gene-based therapies, and technological innovations are expected to enhance the cellular starting materials market over the forecast period.
Cellular starting materials play a crucial role in supporting the development of cell and gene therapies. They are essential for both autologous and allogeneic cell therapies. As the field of cell therapy continues to expand rapidly, the demand for high-quality human cellular starting material is increasingincreases. Cell-based treatments are being investigated for a variety of conditions, including oncology, neurodegenerative disorders, and autoimmune diseases, leading to increased demand for different types of starting materials. Moreover, ongoing advancements in bioprocessing technologies, cell culture techniques, and quality control measures have enhanced the efficiency and scalability of manufacturing cellular starting materials, enabling companies to meet the increasing demand for these materials while maintaining product quality and consistency.
The COVID-19 pandemic had a significant impact onsignificantly impacted the market, with disruptions in supply chains and manufacturing processes leading to shortages and delays in manufacturing timelines. In the case of autologous cell therapies, the pandemic has caused extended patient collection times as patient-derived cells are used as starting material. However, the pandemic also underscored the importance of cell-based therapies and led to increased investments in the sector and accelerated regulatory approvals for some treatments.
However, strict regulations related to cell therapies present a major challenge to the cellular starting materials market. These regulations increase the costs of manufacturing cell and gene therapy products and obtaining the starting material. Various regions around the worldworldwide have established specific regulations governing the collection, processing, and use of cellular starting material for cell therapies. Cellular therapy products meeting specific criteria outlined in 21 CFR 1271.10(a) are regulated solely as Human Cells, Tissues, and Cellular and & Tissue-Based Products (HCT/Ps) under Section 361 of the Public Health Service Act of the U.S.
This product will be delivered within 2 business days.
Cellular starting materials play a crucial role in supporting the development of cell and gene therapies. They are essential for both autologous and allogeneic cell therapies. As the field of cell therapy continues to expand rapidly, the demand for high-quality human cellular starting material is increasingincreases. Cell-based treatments are being investigated for a variety of conditions, including oncology, neurodegenerative disorders, and autoimmune diseases, leading to increased demand for different types of starting materials. Moreover, ongoing advancements in bioprocessing technologies, cell culture techniques, and quality control measures have enhanced the efficiency and scalability of manufacturing cellular starting materials, enabling companies to meet the increasing demand for these materials while maintaining product quality and consistency.
The COVID-19 pandemic had a significant impact onsignificantly impacted the market, with disruptions in supply chains and manufacturing processes leading to shortages and delays in manufacturing timelines. In the case of autologous cell therapies, the pandemic has caused extended patient collection times as patient-derived cells are used as starting material. However, the pandemic also underscored the importance of cell-based therapies and led to increased investments in the sector and accelerated regulatory approvals for some treatments.
However, strict regulations related to cell therapies present a major challenge to the cellular starting materials market. These regulations increase the costs of manufacturing cell and gene therapy products and obtaining the starting material. Various regions around the worldworldwide have established specific regulations governing the collection, processing, and use of cellular starting material for cell therapies. Cellular therapy products meeting specific criteria outlined in 21 CFR 1271.10(a) are regulated solely as Human Cells, Tissues, and Cellular and & Tissue-Based Products (HCT/Ps) under Section 361 of the Public Health Service Act of the U.S.
Cellular Starting Materials Market Report Highlights
- Leukopaks dominated the product segment with a market share of 70.80% in 2023, as they are essential cellular starting materials for cell-based therapies.
- In 2023, GMP dominated the grade segment and held the largest market share in terms of revenue and is expected to grow at the highest CAGR of 22.78% over the forecast period.
- Pharmaceutical and biotechnology companies dominated the end-use market with the largest share of 51.04% in 2023, driven by their significant investment in research and development to bring novel treatments to market, leveraging cellular starting materials as key components in their manufacturing processes.
- Based on end use, tThe CMOs & CROs segment is anticipated to grow at the fastest CAGR due to their increasing adoption and investment in advanced research and manufacturing technologies.
- The North American region dominated the cellular starting materials market with a share of 43.49% owing to factors such as increasing investments in R&D activities, rising demand for cell-based therapies, and advanced healthcare infrastructure.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Cellular Starting Materials Market Variables, Trends & Scope
Chapter 4. Cellular Starting Materials Market: Product Estimates & Trend Analysis
Chapter 5. Cellular Starting Materials Market: Grade Estimates & Trend Analysis
Chapter 6. Cellular Starting Materials Market: End Use Estimates & Trend Analysis
Chapter 7. Cellular Starting Materials Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- AllCells
- Charles River Laboratories
- BioIVT
- NMDP BioTherapies
- CGT GLOBAL
- Excellos
- Anthony Nolan
- STEMCELL Technologies
- HumanCells Bio
- AcceGen
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.16 Billion |
| Forecasted Market Value ( USD | $ 4.84 Billion |
| Compound Annual Growth Rate | 22.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
